Gilotrif Leads Way For The Rest Of Boehringer’s Cancer Pipeline
Executive Summary
Boehringer’s late-stage pipeline also includes the anti-angiogenic nintedanib, which recently demonstrated activity in a subset of patients in a lung cancer trial, and volasertib, a potential first-in-class PLK1 inhibitor.